Drug companies finally have an incentive to carry out safety testing in children following new EU legislation approved last week.

The Open Source software movement has broken the stranglehold of expensive, proprietary products. Could the same thing happen in biotechnology?

An unusual programme by the software giant to spin out its technology has netted nine sales to small companies - with more on the way.

A laser physicist in Saudi Arabia has devised a workable optical diagnostic tool to detect early cancer - and is now looking for partners to commercialise the technology.

A group of researchers, led by Mark Pepys, at University College London has designed and chemically synthesised a new drug, which they have shown to reduce heart tissue damage following a heart attack.

Fujeribio Diagnostics, Inc., based in Japan, has bought Swedish CanAg Diagnostics, merging two leading biotechnology companies in cancer diagnosis.

Microsoft Corp. is spinning out some of its software technology to two small European tech ventures, as part of a program to speed development of innovations from its labs.

On May 26, the US Patent Office issued a preliminary ruling on another long-running patent fight. This battle differs from other high-profile clashes as the challenger is taking on not a big corporate entity, but a broad community of IT researchers and academics.

Europabio thinks that Europe is doing a poor job when it comes to investing in biotechnology.

With global revenues of $110 billion last year, and an aging population, the nascent "neurotechnology" market appears poised for huge growth.